Shares of biopharmaceutical company Soleno Therapeutics, Inc. (SLNO) were in the spotlight on Monday after the company ...

Soleno Therapeutics (SLNO) announced the U.S. commercial availability of VYKAT XR extended-release tablets, the company’s treatment for ...

The sector is defensive, and biopharmaceuticals have, for the most part, limited tariff and transfer price exposure, he ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Highlights:,Insider transactions have been observed within Soleno Therapeutics, with key executives reducing personal holdings.,Analysts from multiple firms have adjusted their outlook on the company, ...

SLNO has been the topic of several other reports. Guggenheim reiterated a “buy” rating and set a $81.00 target price (up from $70.00) on shares of Soleno Therapeutics in a report on Friday ...

Soleno Therapeutics, Inc. (NASDAQ:SLNO), a biopharmaceutical company focused on developing and commercializing novel therapeutics for rare diseases, has recently achieved a significant milestone ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Soleno Therapeutics (SLNO) stock skyrocketed up over 42% this past week on news that it has achieved a significant milestone with FDA approval for VYKAT XR, a pioneering treatment for hyperphagia ...